Business Wire

Nippon Gases Deploys Juniper Networks’ AI-Native Networking Platform to Foster Growth and Accelerate Innovation

12.12.2024 09:00:00 CET | Business Wire | Press release

Share

New wired and wireless network consolidates and transforms operations to underpin mission-critical gas production across Europe

Juniper Networks®, (NYSE: JNPR), a leader in secure, AI-Native Networking, today announced that Nippon Gases, one of the largest industrial gas companies in Europe, has implemented Juniper’s AI-Native wired and wireless LAN solutions to enhance mobile experiences across Nippon Gases’s IT and operational technology (OT) environments whilst streamlining network operations to foster digital innovation. As a key element of Juniper’s AI-Native Networking Platform, the new infrastructure uses Mist AI and cloud native capabilities to provide industry-leading efficiency, resiliency and visibility to Nippon Gases, resulting in exceptional user and operator experiences across offices, specialty labs, manufacturing plants, trucks, pipelines and ships.

With operations in 13 countries, Nippon Gases produces essential gases such as oxygen, nitrogen, hydrogen and carbon dioxide, serving multiple industries including healthcare, food and beverage, manufacturing and biotech.

By standardizing on Juniper’s unique AI for networking capabilities, Nippon Gases accelerates service deployment, simplifies operations, reduces total cost of ownership (TCO) and operational expenses, delivering exceptional end-to-end user and IT experiences. Additionally, Juniper’s AI-Native Networking Platform will help Nippon Gases accelerate new site set ups, increase trouble-ticket resolution with automation, optimize component inventory management and enable efficient, consistent network operations. The IT team can now automate the base configurations for each site and deploy the network rapidly with Zero Touch Provisioning. Role-based access delegates tasks to local teams while maintaining central control, simplifying maintenance through a standardized network. The IT team can put users’ digital experiences first and reduce the IT workload across the entire network life cycle.

News Highlights:

  • Juniper Mist Wireless (Wi-Fi) Assurance provides the fastest way to deploy and the easiest way to manage personalized Wi-Fi experiences, including up to 90 percent elimination in wireless trouble tickets, up to 85 percent fewer truck rolls and up to 9x faster deployment times in some instances. With Juniper, Nippon Gases’ Wi-Fi is fast, secure and reliable, even in the busiest, most experience-critical areas. For instance: reliable Wi-Fi supports seamless communication between industrial IoT devices, sensors and control systems, ensuring uninterrupted operations and real-time monitoring and enables technicians to access and update digital workflows or maintenance logs instantly.
  • Juniper Mist Wired Assurance delivers reliable, secure connectivity experiences for stationary devices and IoT endpoints through AI-driven network operations.
  • Juniper Networks® EX Series Switches enable unified visibility and control over both wireless and wired networking through a common Mist AI engine and microservices cloud infrastructure.
  • Juniper’s Marvis™ Virtual Network Assistant is used across Nippon Gases’ wired and wireless domains to simplify and automate network operations. Acting as an extended member of the IT team, Marvis provides proactive actions and Self-Driving Network™ operations. It continuously optimizes the user experience and provides visibility into impending problems. As a result, IT operations have clear and secure visibility into user and application experiences. AIOps boosts network reliability with automated actions, optimizing the network in real time and enabling rapid troubleshooting when needed.
  • A Juniper Enterprise Agreement (EA) gives Nippon Gases an easier way to purchase, consume and manage the portfolio of Juniper AI-Native Networking Platform software and support services anywhere in its business.

Supporting Quotes:

“Our business is incredibly dynamic and highly competitive. We are frequently building new factories, expanding our footprint and driving growth through acquisitions. These fast-paced changes mean IT typically has little lead time to support the new business demands that keep us ahead of the market. With Juniper’s AI-Native Networking Platform, we can rapidly yet easily deploy networks at new sites, ensuring seamless, secure connectivity and operational readiness. Juniper’s innovative solutions allow us to scale efficiently and consistently, meet business needs on tight timelines, and maintain the high standards our customers expect of a market leader.”

- Bjorn Dupont, IT Network Manager, Nippon Gases

“Nippon Gases needed to harmonize its complex network infrastructure to improve stability and support quality control. Centralized management was a particular challenge, as IT teams had to manage network devices individually across multiple countries. Simplifying network provisioning and operations therefore became a top priority. This requirement plays to our AI-Native Networking Platform’s strengths—offering insight-driven and automated solutions to mitigate manual, decentralized management. With Juniper, Nippon Gases can quickly identify, monitor and correlate network events in real time, proactively addressing potential issues before they impact operations and experiences.”

- Gos Hein van de Wouw, Vice President, Enterprise Sales, EMEA, Juniper Networks

About Juniper Networks

Juniper Networks believes that connectivity is not the same as experiencing a great connection. Juniper's AI-Native Networking Platform is built from the ground up to leverage AI to deliver the best and most secure user experiences from the edge to the data center and cloud. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on X (Twitter), LinkedIn, and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241212532821/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye